Tevogen, the quickly growing Warren-based life sciences company aimed at delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology, said Friday that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.
The funding would be provided under the previously announced grant agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in non-dilutive funding.
KRHP LLC is affiliated with an existing Tevogen investor. The Company expects to direct the expected new $1 million allocation toward accelerating Tevogen.AI’s capabilities to enhance target discovery, shorten development timelines, and improve treatment accessibility for large patient populations.
“Tevogen.AI, our AI initiative, stands at the intersection of innovation and equity,” Tevogen CEO Ryan Saadi said. “This grant is an endorsement of its potential role in accelerating drug development, bringing down costs, speeding up timelines, and expanding access to precision cell therapies for those who need them most.”
The announcement comes at a time of great growth for the company.
In June, it announced it has extended its lease agreement and is expanding its corporate headquarters in Warren — more than doubling its footprint.
The expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development (previously located in Philadelphia), thereby increasing operational efficiency and enhancing cross-team collaboration.
The headquarters will also house Tevogen.AI and the Generics & Biosimilars initiative, with dedicated facilities for Tevogen.AI’s growing team of data scientists and engineers as development of its proprietary AdapTcell and PredicTcell algorithms accelerates.
Saadi said Tevogen remains focused on operating efficiency and strategically deploying funds to maximize shareholder value and patient impact.
